These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108 [TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies. Dampalla CS; Rathnayake AD; Perera KD; Jesri AM; Nguyen HN; Miller MJ; Thurman HA; Zheng J; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Kim Y; Groutas WC; Chang KO J Med Chem; 2021 Dec; 64(24):17846-17865. PubMed ID: 34865476 [TBL] [Abstract][Full Text] [Related]
6. Discovery of SARS-CoV-2 3CL Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507 [TBL] [Abstract][Full Text] [Related]
7. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 M Rut W; Groborz K; Zhang L; Sun X; Zmudzinski M; Pawlik B; Wang X; Jochmans D; Neyts J; Młynarski W; Hilgenfeld R; Drag M Nat Chem Biol; 2021 Feb; 17(2):222-228. PubMed ID: 33093684 [TBL] [Abstract][Full Text] [Related]
10. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756 [TBL] [Abstract][Full Text] [Related]
11. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266 [TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577 [TBL] [Abstract][Full Text] [Related]
14. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
15. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Galasiti Kankanamalage AC; Kim Y; Damalanka VC; Rathnayake AD; Fehr AR; Mehzabeen N; Battaile KP; Lovell S; Lushington GH; Perlman S; Chang KO; Groutas WC Eur J Med Chem; 2018 Apr; 150():334-346. PubMed ID: 29544147 [TBL] [Abstract][Full Text] [Related]
16. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715 [TBL] [Abstract][Full Text] [Related]
17. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*. Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984 [TBL] [Abstract][Full Text] [Related]
18. Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL Adhikari N; Banerjee S; Baidya SK; Ghosh B; Jha T SAR QSAR Environ Res; 2021 Jun; 32(6):473-493. PubMed ID: 34011224 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL Stille JK; Tjutrins J; Wang G; Venegas FA; Hennecker C; Rueda AM; Sharon I; Blaine N; Miron CE; Pinus S; Labarre A; Plescia J; Burai Patrascu M; Zhang X; Wahba AS; Vlaho D; Huot MJ; Schmeing TM; Mittermaier AK; Moitessier N Eur J Med Chem; 2022 Feb; 229():114046. PubMed ID: 34995923 [TBL] [Abstract][Full Text] [Related]
20. Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. Kneller DW; Li H; Galanie S; Phillips G; Labbé A; Weiss KL; Zhang Q; Arnould MA; Clyde A; Ma H; Ramanathan A; Jonsson CB; Head MS; Coates L; Louis JM; Bonnesen PV; Kovalevsky A J Med Chem; 2021 Dec; 64(23):17366-17383. PubMed ID: 34705466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]